Three Generations of DDR Therapeutics – Where Are We Now

Time: 8:10 am
day: Day One


• A landscape overview of the DDR Therapeutic landscape, focusing on the first generation of approved PARP inhibitors
• A detailed look at the preclinical and clinical second generation DDR assets, including; specialized PARP-targeted assets, ATR, and WEE1 inhibitors
• A review of a third generation of novel DDR targets, including POL-Theta, WRN, and PARG